Due to planned maintenance the RACGP website will be offline Tuesday, 12 November 2024 between 7:30AM – 9.30AM AEDT. During this time services will be offline. We apologise for any inconvenience this may cause.
Guideline for the management of knee and hip osteoarthritis
ACR
American College of Rheumatology
AIHW
Australian Institute of Health and Welfare
ASU
avocado/soybean unsaponifiables
BMI
body mass index
CALD
culturally and linguistically diverse
CBT
cognitive behavioural therapy
CENTRAL
Cochrane Database of Systematic Reviews and Cochrane Central Register of Controlled Trials
CI
confidence interval
CINAHL
Cumulative Index to Nursing and Allied Health Literature
COI
conflict of interest
COX
cyclooxygenase
COX-2
cyclooxygenase-2
CRP
C-reactive protein
CT
computed tomography
DALYs
disability-adjusted life-years
DHA
docosahexaenoic acid
DMOADs
disease-modifying osteoarthritis drugs
DMSO
dimethylsulfoxide
EMA
European Medicines Agency
EPA
eicosapentaenoic acid
ESR
erythrocyte sedimentation rate
FGF
fibroblast growth factor
GP
general practitioner
GRADE
Grading of Recommendations Assessment, Development and Evaluation
HANDI
Handbook of non-drug interventions
HOOS
Hip Disability and Osteoarthritis Outcome Score
ICTRP
International Clinical Trials Registry Platform
IgG2
immunoglobulin G2
IL-1
interleukin-1
IPDAS
International Patient Decision Aids Standards
KOOS
Knee Injury and Osteoarthritis Outcome Score
MBS
Medicare Benefits Schedule
MD
mean difference
MRI
magnetic resonance imaging
MSC
mesenchymal stem cell
MSM
methylsulfonylmethane
NATSIHS
National Aboriginal and Torres Strait Islander Health Survey
NGF
nerve growth factor
NHMRC
National Health and Medical Research Council
NICE
National Institute for Health and Care Excellence
NPRS
Numeric Pain Rating Scale
NSAID
nonsteroidal anti-inflammatory drug
OA
osteoarthritis
OARSI
Osteoarthritis Research Society International
OR
odds ratio
p75NTR
75 kDa neurotrophin receptor
PBS
Pharmaceutical Benefits Scheme
PG
prostaglandin
PHN
Primary Health Network
PICO
patient/population/problem, intervention, comparison/control, outcome
PPI
proton-pump inhibitor
PRAC
Pharmacovigilance Risk Assessment Committee
PRP
platelet-rich plasma
RACGP
The Royal Australian College of General Practitioners
RCT
randomised controlled trial
RR
relative risk
SES
socioeconomic status
SMD
standardised mean difference
SNRI
serotonin and norepinephrine reuptake inhibitor
TEAE
treatment-emergent adverse event
TENS
transcutaneous electrical nerve stimulation
TGA
Therapeutic Goods Administration
TNF-alpha
tumour necrosis factor alpha
TrkA
tyrosine kinase receptor
TRPV1
Transient Receptor Potential Vanilloid 1
VAS
Visual Analog Scale
WHO
World Health Organization
WOMAC
Western Ontario and McMaster Universities Osteoarthritis Index
Administrative-report.pdf (PDF 2.76 MB)
Algorithm-Holistic-assessment-diagnosis-and-management-of-knee-and-hip-osteoarthritis.pdf (PDF 0.05 MB)
Guideline-for-the-management-of-knee-and-hip-osteoarthritis-2nd-ed-Appendix-1.pdf (PDF 0.04 MB)
Guideline-for-the-management-of-knee-and-hip-osteoarthritis-2nd-ed-Appendix-2.pdf (PDF 0.05 MB)
Implementation-plan.pdf (PDF 1.79 MB)
Public-consultation-summary.pdf (PDF 0.29 MB)
Technical-document.pdf (PDF 5.79 MB)
Advertising